PYRIDO (2, 3-D) PYRIMIDINONE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS

Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil,...

Full description

Saved in:
Bibliographic Details
Main Authors DILIP BHUMRALKAR, ROBERT STEVEN KANIA, MITCHELL DAVID NAMBU, MICHAEL BRUNO PLEWE, MARY CATHERINE JOHNSON, MASON ALAN PAIRISH, PHUONG THI QUY LE, KHANH TUAN TRAN, KLAUS RUPRECHT DRESS, JACQUI ELIZABET HOFFMAN, HENGMIAO CHENG
Format Patent
LanguageCroatian
English
Published 30.09.2011
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -NR7aR7b ili -N=CR8aR8b, gdje je svaki od navedenih (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C8 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;R3 je (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, halogen, cijano, -(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), COR12, (C8 do C14) aril ili (C2 do C9) heteroaril, gdje su navedeni (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, (C8 do C14) aril i (C2 do C9) heteroaril izborno supstituirani s najmanje jednom skupinom R9;svaki R4 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C8) alkil, (C1 do C6) alkenil, (C1 do C8) alkinil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -C(O)R12-C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkenila, (C1 do C6) alkinila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki R5 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C6) alkil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C6 do C14) aril, (C2 do C9) heteroaril, -S(O)mR12, -S(O)mR11aR11b, -C(O)R12 ili -C(O)NR11aR11b, gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;svaki R6 je neovisno -OH, (C1 do C6) alkinil, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C8) heteroaril, -C(O)R12 -C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkinila, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki od R7a i R7b je neovisno H, (C1 do C8) alkil, (C2 do C6)alkenil, (C2 do C6)alkinil, (C3 do C10) cikloalkil ili (C6 do C10)aril, gdje je svaki od navedenih (C1 do C6) alkila, (C2 do C6)alkenila, (C2 do C6)alkinila, (C3 do C10) cikloalkila, te (C6 do C10)arila izborno supstituiran s najmanje jednom skupinom R9; ili se R7a i R7b može uzeti zajedno s atomom dušika kako bi tvorili The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-Kalpha).
AbstractList Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -NR7aR7b ili -N=CR8aR8b, gdje je svaki od navedenih (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C8 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;R3 je (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, halogen, cijano, -(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), COR12, (C8 do C14) aril ili (C2 do C9) heteroaril, gdje su navedeni (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, (C8 do C14) aril i (C2 do C9) heteroaril izborno supstituirani s najmanje jednom skupinom R9;svaki R4 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C8) alkil, (C1 do C6) alkenil, (C1 do C8) alkinil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -C(O)R12-C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkenila, (C1 do C6) alkinila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki R5 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C6) alkil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C6 do C14) aril, (C2 do C9) heteroaril, -S(O)mR12, -S(O)mR11aR11b, -C(O)R12 ili -C(O)NR11aR11b, gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;svaki R6 je neovisno -OH, (C1 do C6) alkinil, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C8) heteroaril, -C(O)R12 -C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkinila, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki od R7a i R7b je neovisno H, (C1 do C8) alkil, (C2 do C6)alkenil, (C2 do C6)alkinil, (C3 do C10) cikloalkil ili (C6 do C10)aril, gdje je svaki od navedenih (C1 do C6) alkila, (C2 do C6)alkenila, (C2 do C6)alkinila, (C3 do C10) cikloalkila, te (C6 do C10)arila izborno supstituiran s najmanje jednom skupinom R9; ili se R7a i R7b može uzeti zajedno s atomom dušika kako bi tvorili The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-Kalpha).
Author MITCHELL DAVID NAMBU
KLAUS RUPRECHT DRESS
HENGMIAO CHENG
JACQUI ELIZABET HOFFMAN
PHUONG THI QUY LE
ROBERT STEVEN KANIA
DILIP BHUMRALKAR
MARY CATHERINE JOHNSON
MASON ALAN PAIRISH
MICHAEL BRUNO PLEWE
KHANH TUAN TRAN
Author_xml – fullname: DILIP BHUMRALKAR
– fullname: ROBERT STEVEN KANIA
– fullname: MITCHELL DAVID NAMBU
– fullname: MICHAEL BRUNO PLEWE
– fullname: MARY CATHERINE JOHNSON
– fullname: MASON ALAN PAIRISH
– fullname: PHUONG THI QUY LE
– fullname: KHANH TUAN TRAN
– fullname: KLAUS RUPRECHT DRESS
– fullname: JACQUI ELIZABET HOFFMAN
– fullname: HENGMIAO CHENG
BookMark eNrjYmDJy89L5WRwC4gM8nTxV9Aw0lEw1nXRVADxfT1dPP38_VwVnP19A_xD_VyCFRz9XBRCPFw9gxRCg10VHIMVAjyNFTz9PDydPEP8g4J5GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakm8R1CAkYGhoYGZkWFIiKExcaoAHDIumw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
ExternalDocumentID HRP20110621TT1
GroupedDBID EVB
ID FETCH-epo_espacenet_HRP20110621TT13
IEDL.DBID EVB
IngestDate Fri Jul 19 13:59:36 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Croatian
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_HRP20110621TT13
Notes Application Number: HR2011P000621T
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110930&DB=EPODOC&CC=HR&NR=P20110621T1
ParticipantIDs epo_espacenet_HRP20110621TT1
PublicationCentury 2000
PublicationDate 20110930
PublicationDateYYYYMMDD 2011-09-30
PublicationDate_xml – month: 09
  year: 2011
  text: 20110930
  day: 30
PublicationDecade 2010
PublicationYear 2011
RelatedCompanies PFIZER PRODUCTS INC
RelatedCompanies_xml – name: PFIZER PRODUCTS INC
Score 2.8256803
Snippet Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title PYRIDO (2, 3-D) PYRIMIDINONE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110930&DB=EPODOC&locale=&CC=HR&NR=P20110621T1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhT1DeditMpAaUoWFy7ftCHImvT0ghNStvJfBpr14II3XAV_75pXJ1Pe0tycFwOLveR-wC4My19UQ6HC1nXi1zWFDOXraK0ZM1smpepWmmIvgUhNYKJ9jLVpx34aGthRJ_Qb9EckUtUzuW9Fu_1ahvEwiK3cv2UvfOj5bOf2lhatOE-7qAPJezYXsQwcyXXtYNYorEdCaChKil3lfa4HW024uC9Ok1Zyuq_TvGPYT_i6Kr6BDpF1YNDtx291oODcPPjzZcb4Vufgh-9xQQzdK8-opGMH1CzDwkmlFEPuSyM2ITiBI0pRmngkRhNEg-NExSRESI0IA5JWZycwa3vpW4gc4Jmf9efBfGW-FQZnUO3WlbFBSAr15XcUOdzrpS1rJlxzrlbzEtuVZhqqWd9GOzCdLkbfAVHv_HTJjdiAN3686u45gq4zm4E434Aw-6Bug
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8BhTnG86FT-mBpSiYHHt-kEfimxNS6JrWtpO5tNYuxZE6Iar-PdN4-Z82luSg-NycLmP3AfArWnps6Lbncm6nmeyppiZbOWFJWtm3bxM1QpD9C3wmUFG2vNYHzfgY10LI_qEfovmiFyiMi7vlXivF5sgFha5lcvH9J0fzZ-8xMbSbB3u4w56V8ID2w0DHDiS49gkklhkhwJoqErCXaUdbmObtTi4r4O6LGXxX6d4B7AbcnRldQiNvGxDy1mPXmvDnr_68ebLlfAtj8AL3yKKA3SnPqCejO9RvfcppixgLnICPwxGDMeozzBKiEsjNIpd1I9RSHuIMkIHNAmi-BhuPDdxiMwJmvxdf0KiDfGJ0juBZjkv81NAVqYrmaFOp1wpa2k945xzN58W3Kow1UJPz6CzDdP5dvA1tEjiDydDyl4uYP83llrnSXSgWX1-5ZdcGVfplWDiDwWehK0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PYRIDO+%282%2C+3-D%29+PYRIMIDINONE+COMPOUNDS+AND+THEIR+USE+AS+PI3+INHIBITORS&rft.inventor=DILIP+BHUMRALKAR&rft.inventor=ROBERT+STEVEN+KANIA&rft.inventor=MITCHELL+DAVID+NAMBU&rft.inventor=MICHAEL+BRUNO+PLEWE&rft.inventor=MARY+CATHERINE+JOHNSON&rft.inventor=MASON+ALAN+PAIRISH&rft.inventor=PHUONG+THI+QUY+LE&rft.inventor=KHANH+TUAN+TRAN&rft.inventor=KLAUS+RUPRECHT+DRESS&rft.inventor=JACQUI+ELIZABET+HOFFMAN&rft.inventor=HENGMIAO+CHENG&rft.date=2011-09-30&rft.externalDBID=T1&rft.externalDocID=HRP20110621TT1